Flumazenil: Difference between revisions
m (Protected "Flumazenil": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
| Line 21: | Line 21: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Flumazenil''' (also known as '''flumazepil''', code name '''[[List of pharmaceutical compound number prefix|Ro]] 15-1788''', trade names '''Anexate''', '''Lanexat''', '''Mazicon''', '''Romazicon''') is a [[benzodiazepine]] [[receptor antagonist|antagonist]], used as an [[antidote]] in the treatment of benzodiazepine [[overdose]]. It reverses the effects of benzodiazepines by [[competitive inhibitor|competitive inhibition]] at the benzodiazepine binding site on the [[GABA A receptor|GABA<sub>A</sub>]] [[receptor (biochemistry)|receptor]]. It was introduced in 1987 by [[Hoffmann-La Roche]] under the trade name '''Anexate'''. | '''Flumazenil''' (also known as '''flumazepil''', code name '''[[List of pharmaceutical compound number prefix|Ro]] 15-1788''', trade names '''Anexate''', '''Lanexat''', '''Mazicon''', '''Romazicon''') is a [[benzodiazepine]] [[receptor antagonist|antagonist]], used as an [[antidote]] in the treatment of benzodiazepine [[overdose]]. It reverses the effects of benzodiazepines by [[competitive inhibitor|competitive inhibition]] at the benzodiazepine binding site on the [[GABA A receptor|GABA<sub>A</sub>]] [[receptor (biochemistry)|receptor]]. It was introduced in 1987 by [[Hoffmann-La Roche]] under the trade name '''Anexate'''. | ||
Revision as of 02:46, 9 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Elimination half-life | 7-15 min (initial) 20-30 min (brain) 40-80 min (terminal) |
| Excretion | Urine 90-95% Feces 5-10% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H14FN3O3 |
| Molar mass | 303.288 g/mol |
|
WikiDoc Resources for Flumazenil |
|
Articles |
|---|
|
Most recent articles on Flumazenil |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Flumazenil at Clinical Trials.gov Clinical Trials on Flumazenil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Flumazenil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Flumazenil Discussion groups on Flumazenil Patient Handouts on Flumazenil Directions to Hospitals Treating Flumazenil Risk calculators and risk factors for Flumazenil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Flumazenil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Flumazenil (also known as flumazepil, code name Ro 15-1788, trade names Anexate, Lanexat, Mazicon, Romazicon) is a benzodiazepine antagonist, used as an antidote in the treatment of benzodiazepine overdose. It reverses the effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site on the GABAA receptor. It was introduced in 1987 by Hoffmann-La Roche under the trade name Anexate.
The onset of action is rapid and usually effects are seen within one to two minutes. The peak effect is seen at six to ten minutes. The recommended dose for adults is 200 μg every 1-2 minutes until the effect is seen, to a maximum of 3 mg per hour. It is available as a clear, colourless solution for intravenous injection, containing 500 μg in 5 mls.
All benzodiazepines (including midazolam) have longer half-lives than flumazenil. Therefore, repeat doses of flumazenil may be required to prevent recurrent symptoms of overdosage once the initial dose of flumazenil wears off. It is hepatically metabolised to inactive compounds which are excreted in the urine. Subjects who are physically dependent on benzodiazepines may suffer benzodiazepine withdrawal symptoms, including seizure, upon administration of flumazenil.
See also
References
- Romazicon product information, Roche USA
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antidotes
- Benzodiazepines
- Organofluorides
- GABA antagonists